1045223D Printing of Pharmaceutical Products for Bespoke Medicinal DeliveryClosedCollaborative R&DISCF"This innovation is focused on improving the production of solid-dose medicines (tablets). Currently, capitally intensive processes are used to produce large volumes of identical tablets. The applicants have identified clear market demand for a flexible point-of-dispensing, manufacturing approach such that bespoke tablet formulations can be produce on a desktop machine. Such an approach can provide greater control of the dose strength enabling medications to be personalised to recipient's needs. This team is developing such a novel 3D tablet printing ""3DP"" manufacturing and supply chain. The vision is to produce bespoke doses of personalised medicines. As an example, a long-term goal is to enable production of personalised multi-drug combinations for a patient or defined group of patients with cognitive impairment such that their entire multi-faceted dosage regimen is drastically simplified; such a ""polypill"", even in a simpler, non-personalised form, has been a long-established goal for dosing to elderly patients but the development is not feasible using standard manufacturing processes. This team's commercial goal is to create the systems and materials which enable production of validated, traceable pharmaceutical products which are suitable for human use, and commercially to establish printing as a pharmaceutical development service to companies researching personalisation of medicines. Contextually, partner 1 (Katjes Fassin) has developed a food grade 3D printing system. FabRx (the leading pharmaceutical 3D printing specialists) wishes to adopt and modify this system for use in the pharmaceutical sector. The challenge is; 1 -- limited validation of use of the types of food grade materials that form the basis of the 3DP tablets and 2 -- development of the tablet production hardware to provide in-situ confirmation of the table dose (key regulatory requirement)."